Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial.

[1]  C. Antzelevitch,et al.  Inhibition of late (sustained/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function , 2004 .

[2]  Andrew C. Zygmunt,et al.  Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties , 2004, Circulation.

[3]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[4]  C. Antzelevitch,et al.  Antiarrhythmic Effects of Ranolazine in a Guinea Pig in Vitro Model of Long-QT Syndrome , 2004, Journal of Pharmacology and Experimental Therapeutics.

[5]  J. Shryock,et al.  Antagonism by Ranolazine of the Pro-Arrhythmic Effects of Increasing Late INa in Guinea Pig Ventricular Myocytes , 2004, Journal of cardiovascular pharmacology.

[6]  B. Chaitman,et al.  Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. , 2004, Journal of the American College of Cardiology.

[7]  J. M. Di Diego,et al.  Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent , 2004, Journal of cardiovascular pharmacology and therapeutics.

[8]  B. Chaitman,et al.  Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. , 2004, JAMA.

[9]  B. Chaitman,et al.  Ranolazine increases exercise performance and decreases hemoglobin A1C in angina patients with diabetes , 2003 .

[10]  Donald M Bers,et al.  Intracellular Na+ regulation in cardiac myocytes. , 2003, Cardiovascular research.

[11]  E. Topol,et al.  Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable Angina: One-Year Survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV—Acute Coronary Syndrome) Trial , 2003, Circulation.

[12]  M. Chandler,et al.  Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. , 2002, Journal of cardiac failure.

[13]  Colleen E Clancy,et al.  Defective cardiac ion channels: from mutations to clinical syndromes. , 2002, The Journal of clinical investigation.

[14]  Carl J Pepine,et al.  ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.

[15]  J. W. Schaeffer,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary article , 2002 .

[16]  M. Chandler,et al.  Short-Term Treatment With Ranolazine Improves Mechanical Efficiency in Dogs With Chronic Heart Failure , 2002, Circulation research.

[17]  W. Stanley,et al.  Partial fatty acid oxidation inhibitors: a potentially new class of drugs for heart failure , 2002, European journal of heart failure.

[18]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[19]  C. Pepine,et al.  A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. , 1999, The American journal of cardiology.

[20]  E. Murphy,et al.  Sodium regulation during ischemia versus reperfusion and its role in injury. , 1999, Circulation research.

[21]  T. Nishimura,et al.  Intracellular sodium accumulation during ischemia as the substrate for reperfusion injury. , 1999, Circulation research.

[22]  J. Mccormack,et al.  Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. , 1994, Cardiovascular research.

[23]  M. Stern,et al.  Ionic basis of ischaemic cardiac injury: insights from cellular studies. , 1994, Cardiovascular research.

[24]  P. Gage,et al.  A persistent sodium current in rat ventricular myocytes. , 1992, The Journal of physiology.

[25]  R. Campbell,et al.  Arrhythmogenesis and programmed stimulation techniques. , 1988, European heart journal.

[26]  T R Fleming,et al.  Designs for group sequential tests. , 1984, Controlled clinical trials.

[27]  J. Mccormack,et al.  Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. , 1996, Circulation.